B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model

Abstract One obstacle for human solid tumor immunotherapy research is the lack of clinically relevant animal models. In this study, we sought to establish a chimeric antigen receptor (CAR) T-cell treatment model for naturally occurring canine sarcomas as a model for human CAR T-cell therapy. Canine CARs specific for B7-H3 were constructed using a single-chain variable fragment derived from the human B7-H3–specific antibody MGA271, which we confirmed to be cross-reactive with canine B7-H3. After refining activation, transduction, and expansion methods, we confirmed target killing in a tumor spheroid three-dimensional assay. We designed a B7-H3 canine CAR T-cell and achieved consistently high levels of transduction efficacy, expansion, and in vitro tumor killing. Safety of the CAR T cells were confirmed in two purposely bred healthy canine subjects following lymphodepletion by cyclophosphamide and fludarabine. Immune response, clinical parameters, and manifestation were closely monitored after treatments and were shown to resemble that of humans. No severe adverse events were observed. In summary, we demonstrated that similar to human cancers, B7-H3 can serve as a target for canine solid tumors. We successfully generated highly functional canine B7-H3–specific CAR T-cell products using a production protocol that closely models human CAR T-cell production procedure. The treatment regimen that we designed was confirmed to be safe in vivo. Our research provides a promising direction to establish in vitro and in vivo models for immunotherapy for canine and human solid tumor treatment.

[1]  A. Davidoff,et al.  A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells , 2021, Frontiers in Immunology.

[2]  Robin L. Jones,et al.  IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy , 2021, Journal for ImmunoTherapy of Cancer.

[3]  J. Rossmeisl,et al.  Veterinary Cooperative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG‐CTCAE v2) following investigational therapy in dogs and cats , 2021, Veterinary and comparative oncology.

[4]  Lung-Ji Chang,et al.  Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate. , 2020, Veterinary immunology and immunopathology.

[5]  H. Heslop,et al.  Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma , 2020, Nature Communications.

[6]  Shondra M. Pruett-Miller,et al.  Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells , 2020, Molecular therapy oncolytics.

[7]  Derek W. Yecies,et al.  Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors , 2020, Nature Medicine.

[8]  Meijia Yang,et al.  B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors , 2020, Molecular therapy oncolytics.

[9]  M. Atherton,et al.  Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma , 2019, Oncoimmunology.

[10]  N. Mason Comparative Immunology and Immunotherapy of Canine Osteosarcoma. , 2020, Advances in experimental medicine and biology.

[11]  Meijia Yang,et al.  B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma , 2019, Molecular therapy oncolytics.

[12]  Winnie S. Liang,et al.  Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2 , 2019, Communications Biology.

[13]  D. Maloney,et al.  The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. , 2019, Blood.

[14]  E. Moon,et al.  CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment , 2019, Front. Immunol..

[15]  P. Sorensen,et al.  CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors , 2019, Clinical Cancer Research.

[16]  T. Blankenstein,et al.  Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regression , 2018, The Journal of clinical investigation.

[17]  J. Carpten,et al.  Profiling targetable immune checkpoints in osteosarcoma , 2018, Oncoimmunology.

[18]  Zev A. Binder,et al.  Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas , 2018, Molecular therapy oncolytics.

[19]  P. Dong,et al.  B7H3 As a Promoter of Metastasis and Promising Therapeutic Target , 2018, Front. Oncol..

[20]  Z. Mourelatos,et al.  High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model , 2017, Cancer Immunology Research.

[21]  T. Mak,et al.  Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function , 2017, Cell Research.

[22]  D. Busch,et al.  Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. , 2016, The Journal of clinical investigation.

[23]  D. Powell,et al.  Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Christine E Brown,et al.  Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. , 2016, Blood.

[25]  K. Flaherty,et al.  Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 , 2015, Journal of Immunotherapy for Cancer.

[26]  C. Rooney,et al.  Toward Immunotherapy With Redirected T Cells in a Large Animal Model: Ex Vivo Activation, Expansion, and Genetic Modification of Canine T Cells , 2014, Journal of immunotherapy.

[27]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[28]  Hua Yu,et al.  B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma , 2013, The Journal of investigative dermatology.

[29]  J. Dobson Breed-Predispositions to Cancer in Pedigree Dogs , 2013, ISRN veterinary science.

[30]  P. Moore,et al.  Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity , 2012, Clinical Cancer Research.

[31]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[32]  S. Riddell,et al.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. , 2011, Blood.

[33]  R. Storb,et al.  Antagonistic and Agonistic Anti-canine CD28 Monoclonal Antibodies: Tools for Allogeneic Transplantation , 2011, Transplantation.

[34]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  P. Meltzer,et al.  Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression , 2009, BMC Genomics.

[36]  M. Potter,et al.  Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy , 2002, Gene Therapy.

[37]  R. Storb,et al.  Canine T cells transduced with a herpes simplex virus thymidine kinase gene: a model to study effects on engraftment and control of graft-versus-host disease. , 1998, Transplantation.